Opinion

Video

Overview of Non–Clear Cell RCC

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Rachel N. Grisham, MD
Bradley McGregor, MD
William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center
Regina Barragan-Carrillo, MD
4 experts are featured in this series.
Kathryn E. Beckermann, MD, PhD
Related Content
RCC | Image Credit: © Crystal light – stock.adobe.com
March 19th 2025

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

Oncology Unplugged With Dr Chandler Park
February 26th 2025

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

Casdatifan in ccRCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 12th 2025

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
February 17th 2025

Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

Cemiplimab Plus Chemotherapy in Advanced/Metastatic Penile Carcinoma | Image Credit: © Katsyarina – stock.adobe.com
March 11th 2025

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma

Kidney Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Latent Viruses in Human Genome Inspire Novel Directions for Kidney Cancer Immunotherapy